65,437 trials
KRAS Gene Mutation · Metastatic Malignant Neoplasm in the Brain · Recurrent Non-Small Cell Lung Carcinoma
Primary: Progression Free Survival (PFS) — 3.7 months
Urethra Issue · Pelvic Organ Prolapse · Urinary Incontinence
Primary: Sensation as Indicated by the Volume of Water Filled (ml) at the Time of Patient Perception of First Sensation, First Urge to Void, Strong Urge to Void, and Full Bladder…
Glioblastomas · Sarcoma · Astrocytoma
Primary: Percentage of Eligible Dyads (Parent-child) Who Enroll During a Two-year Period — 100; 100 percentage of dyads
Surgical Skin Preparation
Primary: Log Change (Reduction) in Skin Flora on the Inguinal Region at 10 Minutes — 3.60; 3.61; 1.15 Log10 CFU/cm^2
Hepatic Impairment · Moderate Impaired Hepatic Function
Primary: Maximum Plasma Concentration (Cmax) of Quizartinib Following Single Dose of Quizartinib in Participants With Moderate Hepatic Impairment Compared to Participants With…
Colorectal Cancer · Social Determinants of Health
Primary: Conditional Odds Ratio of Patients Screened for Colorectal Cancer During Intervention Compared to Patients Screened During Usual Care — 0.068; 0.028 Conditional odds…
Cigarette Smoking
Primary: 7-day Point Prevalence Smoking Abstinence Levels — 4; 22; 18; 6 Participants — p=<0.001
Lip Aging · Lip Augmentation · Lip
Primary: Change in Lip Vessel's Thickness — 0.833; 0.360 µm
Alcoholic Hepatitis
Primary: Survival at 90 Days — 90; 70 percentage of participants
Healthy
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Tepotinib in Treatment A and Treatment C — 21722; 23649…
Tobacco Use Disorder
Primary: Nicotine Delivery — 14.13; 6.79; 9.15 ng/mL — p=0.002
Cystic Fibrosis
Primary: Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment- Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 160; 26…
Amyotrophic Lateral Sclerosis
Primary: Parts A and B: Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs) — 2; 2; 3; 3 Participants
Coronavirus Disease (COVID-19)
Primary: Main Part: Geometric Mean Titers (GMT) Ratio of Neutralizing Antibody Titers to the Ancestral Strain (Wild-type Virus) on Day 15 Compared With That Observed on Day 36 in…
Aging
Primary: Walking Speed Change From Baseline — .054; .078; .085; .039 meters/second